[HTML][HTML] Baricitinib in patients with refractory rheumatoid arthritis

…, WL Macias, S de Bono, DE Schlichting… - … England Journal of …, 2016 - Mass Medical Soc
Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

…, G Rocha, NL Byers, DE Schlichting… - EMBO molecular …, 2020 - embopress.org
Baricitinib is an oral Janus kinase ( JAK )1/ JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis ( RA ) that was independently predicted, using artificial intelligence ( AI ) …

[HTML][HTML] Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

…, PC Taylor, E Drescher, DE Schlichting… - Annals of the …, 2015 - ard.bmj.com
Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral
inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite …

[HTML][HTML] Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological …

…, CL Gaich, AM DeLozier, DE Schlichting… - Annals of the …, 2017 - ard.bmj.com
Objectives To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately
to severely active rheumatoid arthritis, who had insufficient response or intolerance to …

[HTML][HTML] Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis

EC Keystone, MC Genovese, DE Schlichting… - The Journal of …, 2018 - jrheum.org
Objective. To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis
(RA) up to 128 weeks in a phase IIb study (NCT01185353). Methods. After a 24-week …

[HTML][HTML] Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial

…, X Zhang, CL Dickson, DE Schlichting… - Journal of clinical …, 2019 - mdpi.com
The purpose of the study was to assess the proportion of patients who achieve pain relief
thresholds, the time needed to reach the thresholds, and the relationship between pain and …

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

…, JM Kremer, CE Kartman, DE Schlichting… - …, 2018 - academic.oup.com
Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet
medical need. We evaluated the effects of baseline characteristics, including prior bDMARD …

[PDF][PDF] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib

…, L Sinigaglia, DE Schlichting… - Clin Exp …, 2019 - clinexprheumatol.org
Numerous cytokines have been implicated in the pathogenesis of inflammatory diseases,
and their dysregulation is a main feature of rheumatoid arthritis (RA). Cytokines stimulate …

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

…, MA Connelly, WL Macias, DE Schlichting… - Annals of the …, 2018 - ard.bmj.com
Objectives Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA)
and may be further modified by treatment with Janus kinase inhibitors and other disease-…

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis

…, DE Schlichting, VL Crotzer, E Nantz… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the effects of baricitinib on lipid profiles in patients with moderate‐to‐severe
rheumatoid arthritis. Methods Treatment with once‐daily doses of baricitinib (1, 2, 4, or …